Add BrightSurf on Google Email

Rice-BCM research achieves gene-editing breakthrough that could improve treatment for liver disease, other disorders

The Rice University lab, in collaboration with Baylor College of Medicine, has developed a new gene-editing strategy called Repair Drive that improves the effectiveness of gene therapies in the liver. The technique enables the repair of liver cells at higher rates and equips them with a selective advantage to outcompete incorrectly edi...

SourceRice University·JournalScience Translational Medicine·TypeExperimental study·DateFeb 13, 2025

Splicing twins: unravelling the secrets of the minor spliceosome complex

Researchers in the Galej Group at EMBL Grenoble have provided new structural insights into the U11 snRNP subunit of the minor spliceosome, revealing its ability to specifically identify rare substrates. The study sheds light on the complex assembly pathway of the minor spliceosome, which is critical for processing minor introns in genes.

SourceEuropean Molecular Biology Laboratory·JournalMolecular Cell·TypeExperimental study·DateFeb 12, 2025

Activating complex regions of the genome to treat rare diseases

Scientists at Duke University have discovered a master epigenetic switch that can be activated using CRISPR to compensate for missing genes in Prader-Willi syndrome. This approach could potentially treat the disease by turning on naturally suppressed genes from one parent, addressing the underlying genetic defect.

SourceDuke University·JournalCell Genomics·TypeExperimental study·DateFeb 12, 2025

Gene therapy may be “one shot stop” for rare bone disease

A new study adds weight to the safety and effectiveness of a gene therapy for hypophosphatasia, a rare inherited disorder that causes abnormal bone development. The treatment, AAV8-TNAP-D10, has shown promising results in mice models, with female mice achieving improvements in bone and teeth at lower doses.

SourceSanford Burnham Prebys·JournalJournal of Bone and Mineral Research·TypeExperimental study·DateFeb 3, 2025

Previous experience affects family planning decisions of people with hereditary dementia

A new study led by UCL researchers reveals that people at risk of hereditary dementia significantly impact their choices about having children and parenting. Genetic risk is viewed in the context of other factors, with concerns including practical and emotional challenges of caring for someone with familial frontotemporal dementia.

SourceUniversity College London·JournalJournal of Genetic Counseling·TypeSurvey·DateJan 13, 2025

A new era in genetic engineering

Researchers have developed a new genetic engineering tool, mvGPT, that can precisely edit genes, activate gene expression, and repress genes all at the same time. The technology has shown promise in treating genetic diseases such as Wilson's disease and type I diabetes by targeting multiple genetic conditions simultaneously.

SourceUniversity of Pennsylvania School of Engineering and Applied Science·JournalNature Communications·TypeExperimental study·DateJan 8, 2025

Breakthrough study reveals bumetanide treatment restores early social communication in fragile X syndrome mouse model

Researchers found that bumetanide treatment normalizes neonatal social communication in newborn pups with the fragile X mutation, but reduces post-pubertal social interaction. The study suggests stage-specific effects on social development and raises questions about timing and dosing of bumetanide for targeted interventions.

SourceGenomic Press·JournalGenomic Psychiatry·DateDec 24, 2024

Michael Courtney of Turku Bioscience Center receives grant for research on SYNGAP1 missense variants and drug repurposing from SynGAP Research Fund (SRF) dba Cure SYNGAP1

Dr. Michael Courtney's team will use advanced phenotyping techniques to assess how SYNGAP1 missense variants impact protein function, focusing on pathogenic or uncertain variants. The project aims to inform therapeutic strategies for patients with SYNGAP1-related disorders through drug repurposing and functional assays.

Special issue: Osteogenesis imperfecta from bench to bedside and from cradle to grave

This special issue of Calcified Tissue International presents a collection of critical reviews and original research articles on osteogenesis imperfecta (OI), covering essential aspects of the condition, including its nosology, genetics, and clinical presentation. The contributions also discuss treatment strategies for both children an...

SourceInternational Osteoporosis Foundation·TypeCommentary/editorial·DateNov 29, 2024

Bringing genomics into public policy requires greater awareness, professional training, and investment

The WHO's Technical Advisory Group on Genomics published an article outlining challenges and actions to promote the use of genomics in public health. The group aims to increase awareness and provide technical guidance to accelerate access to genetic technologies, enabling preventive measures and targeted treatment for various diseases.

Cancer genetic risk assessment guidelines expand to meet growing understanding of hereditary risk

The National Comprehensive Cancer Network has updated its guidelines for genetic/familial high-risk assessment, incorporating the latest scientific research and expert recommendations to enhance screening practices and treatment options. The expanded guidelines cover various cancer types and provide guidance on genetic testing, heredit...

Use of “genetic scissors” carries risks

The CRISPR tool was successfully used to correct a genetic defect in cells affected by chronic granulomatous disease. However, the repair process also introduced new genetic defects, highlighting the need for caution when using CRISPR technology in clinical settings.

SourceUniversity of Zurich·JournalCommunications Biology·TypeExperimental study·DateNov 6, 2024

Identified 51 amyotrophic lateral sclerosis-associated mutations that could help diagnose the disease

A recent study has identified 51 amyotrophic lateral sclerosis (ALS)-associated mutations in mitochondrial DNA that could help diagnose the disease. The mutations, which include 13 that increase the risk of ALS and 38 protective ones, were found to be significantly associated with an increased or decreased risk of developing the disease.

Novel artificial intelligence-based method for pathological diagnosis of hereditary kidney diseases

Researchers developed an AI-based method to analyze kidney lesions in female patients with Alport syndrome, predicting renal prognosis and guiding treatment interventions. The approach uses a modified stain and deep learning to detect basement membrane lesions, showing a positive correlation with proteinuria concentration.

SourceUniversity of Tsukuba·JournalAmerican Journal Of Pathology·DateOct 30, 2024

ClinGen creates a robust, open-access platform to define the clinical relevance of genes and variants

The Clinical Genome Resource (ClinGen) has published data on over 2,700 genes curated for clinical relevance to genetic diseases. The consortium has identified 2,420 gene-disease relationships, classified 5,161 unique pathogenic variants and validated 1,557 genes for dosage sensitivity assessments.

SourceBaylor College of Medicine·JournalGenetics in Medicine·TypeComputational simulation/modeling·DateOct 24, 2024

Study shows that Rett syndrome in females is not just less severe, but different

Researchers found that female mouse models of Rett syndrome have a mosaic-like distribution of cells expressing wild-type and mutant MeCP2 protein, leading to dysregulated genes. The study also discovered an unusual disease progression, with females having more dysregulated genes at the pre-symptomatic stage than later on.

SourceUniversity of California - Davis Health·JournalCommunications Biology·TypeExperimental study·DateOct 17, 2024

Study busts myths about cause of gout

A genome-wide association study found that inherited genetics is a key factor in why some people develop gout, while others don't. The research identified new targets for preventing gout attacks and hopes to lead to improved treatment options.

SourceUniversity of Otago·JournalNature Genetics·DateOct 15, 2024

A new study reveals a promising therapy using a molecule that blocks microRNAs to treat myotonic dystrophy type 1

A new study reveals a promising therapy using antimiRs to treat myotonic dystrophy type 1 (DM1), a genetic disorder caused by abnormally high CTG repeats in the DMPK gene. The treatment increased MBNL1 levels and improved muscle cell functions, reducing disease symptoms.

SourceGermans Trias i Pujol Research Institute·JournalScience Advances·TypeExperimental study·DateOct 14, 2024